anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method (10) for preparing stable liquid emulsion forms of plant extract is provided. A plant extract is mixed (11) with a diluent oil as an oil mixture. Heat is applied (13) to the oil mixture until the mixture reaches a threshold viscosity. An emulsifying agent is dispersed (14) in water as an emulsifying solution. The oil mixture and emulsifying solution are mixed (16) together. The mixed oil mixture and emulsifying solution are homogenized (17) as a liquid form of the plant extract.
The present invention provides a stable pharmaceutical composition which contains an acetic acid class of non-steroidal anti-inflammatory drug (NSAID), a phosphate solution, an isotonic agent, and water. The pharmaceutical composition is particularly suitable for parenteral injection such as intravenous or intramuscular injection. The preferred NSAID is ketorolac tromethamine, which includes any racemic mixture of [−]S and [+]R ketorolac tromethamine. The preferred phosphate solution contains sodium phosphate monobasic (NaH 2 PO 4 ) or potassium phosphate monobasic (KH 2 PO 4 ), with or without crystalline water. The preferred isotonic agent is NaCl. The pharmaceutical composition is preferably at pH 6.0 to 8.5 and with osmolarity within 0.5 to 3.
PURPOSE: A nervous system disease prevention or treatment composition containing pomegranate extracts is provided to reduce the oxidative stress induction, and to enhance the cell activation. CONSTITUTION: A nervous system disease prevention or treatment composition contains pomegranate extracts. The nervous system disease is a disease which induces the neuronal cell damage by the amyloid beta peptide-inducing oxidative stress. The nervous system disease is alzheimer disease. The pomegranate extracts are obtained by ethanol. The nervous system disease prevention or treatment composition contains 2,4-bis(1,1-dimethylethyl)-phenol which is extracted from the pomegranate extracts.
The purpose of this study was to present the preliminary results of the PLATFORM Study, which aimed to evaluate the effectiveness of precision treatment for rare tumors in China. This study involved a phase II, open-label, non-randomized, multi-arm, single-center clinical trial. Patients with advanced rare solid tumors, who had not responded to standard treatment, were enrolled. The primary objective was to assess the safety and efficacy of targeted therapies in patients with actionable genetic alterations and immune checkpoint inhibitors in patients lacking actionable genetic alterations. Out of the 922 cases screened, 107 patients underwent mutation detection, with a final enrollment of 64 cases for the study. Among these, 26 cases received targeted therapy, and 38 cases underwent immunotherapy. The study encompassed over 40 types of rare tumors. The overall objective response rate (ORR) was 7.0%, with a disease control rate (DCR) of 70%. Targeted therapy showed a higher ORR of 17.8% and a DCR of 100%. The median progression-free survival (PFS) was 4 months overall, with targeted therapy showing a median PFS of 5 months and immunotherapy showing a median PFS of 3 months. In conclusion, from this preliminary analysis, targeted therapy within the precision medicine framework demonstrated promising therapeutic potential for rare tumors. However, monotherapy immunotherapy exhibited limited efficacy, highlighting the challenges in overcoming tumor-specific variations. These findings underscore the importance of further research and the exploration of combination therapies to improve outcomes for patients with rare tumors.
Antiangiogenic drugs and tyrosine kinase inhibitor (TKI) represent a new therapeutic issue in the treatment of several neoplasic tumors (colon, kidney, breast, lung, skin) and hemopathy. Antiangiogenic drugs acts through neutralization of the activity (e.g. bevacizumab) or the inhibition of post-receptor tyrosine kinase pathways (e.g. sunatinib, sorafenib), leading to a reduction and inhibition of the tumoral tissular neovascularization. Due to the ubiquitous role of and the systemic administration of the antiangiogenic drugs, almost all of them are responsible for several side effects, many involving the cardiovascular system (e.g. arterial hypertension, cardiomyopathies, proteinuria, bleedings,...) and leading to a reduction of the doses or withdrawal of the treatment. To date, the mechanism and the impact of these cardiovascular effects is not well understood involving structural (i.e. capillary rarefaction) and functional vascular dysfunction (i.e. vasomotor dysfunction, stiffening).
Patient-derived organoids (PDOs) may facilitate treatment selection. This retrospective cohort study evaluated the feasibility and clinical benefit of using PDOs to guide personalized treatment in metastatic breast cancer (MBC). Patients diagnosed with MBC were recruited between January 2019 and August 2022. PDOs were established and the efficacy of customized drug panels was determined by measuring cell mortality after drug exposure. Patients receiving organoid-guided treatment (OGT) were matched 1:2 by nearest neighbor propensity scores with patients receiving treatment of physician's choice (TPC). The primary outcome was progression-free survival. Secondary outcomes included objective response rate and disease control rate. Targeted gene sequencing and pathway enrichment analysis were performed. Forty-six PDOs (46 of 51, 90.2%) were generated from 45 MBC patients. PDO drug screening showed an accuracy of 78.4% (95% CI 64.9%-91.9%) in predicting clinical responses. Thirty-six OGT patients were matched to 69 TPC patients. OGT was associated with prolonged median progression-free survival (11.0 months vs. 5.0 months; hazard ratio 0.53 [95% CI 0.33-0.85]; p = .01) and improved disease control (88.9% vs. 63.8%; odd ratio 4.26 [1.44-18.62]) compared with TPC. The objective response rate of both groups was similar. Pathway enrichment analysis in hormone receptor-positive, human epidermal growth factor receptor 2-negative patients demonstrated differentially modulated pathways implicated in DNA repair and transcriptional regulation in those with reduced response to capecitabine/gemcitabine, and pathways associated with cell cycle regulation in those with reduced response to palbociclib. Our study shows that PDO-based functional precision medicine is a feasible and effective strategy for MBC treatment optimization and customization.
PURPOSE: An adult stem cell line containing a hepatocyte growth factor(HGF) gene and a neurogenic transcription factor gene with basic helix-ring-helix(bHLH) is provided to overcome chronic physical disability. CONSTITUTION: An adult stem cell line is transfected with a HGF(hepatocyte growth factor) gene and a neurogenic transcription factor gene of basic helix-loop-helix(bHLH). The adult stem cell line is a mesenchymal stem cell line. The neurogenic transcription factor is neurogenin 1, neurognin 2, neuro D1, MASH1, MATH 3, or E47 transcription factor of a fragment thereof. The HGF gene contains a nucleotide sequence of sequence number 1. A method for preparing the adult stem cell line comprises: a step of culturing the adult stem cells; a step of transfecting neurogenin 1 gene into the adult stem cells; a step of sorting neurogenin 1 gene-transfected adult stem cells; a step of introduicing the HGF gene into the adult stem cells; a step of selecting the adult stem cells containing neurogenin 1 gene and HGF gene; and a step of culturing the sorted adult stem cells.
Human experience of overdose with FASLODEX is limited. There are isolated reports of overdose with FASLODEX in humans. No adverse reactions were seen in healthy male and female volunteers who received intravenous fulvestrant, which resulted in peak plasma concentrations at the end of the infusion, that were approximately 10 to 15 times those seen after intramuscular injection. The potential toxicity of fulvestrant at these or higher concentrations in cancer patients who may have additional comorbidities is unknown. There is no specific treatment in the event of fulvestrant overdose, and symptoms of overdose are not established. In the event of an overdose, healthcare practitioners should follow general supportive measures and should treat symptomatically.
<P>PROBLEM TO BE SOLVED: To provide a base material for pasting transdermal medicine economical because of requiring a small amount of transdermal medicine, good in adhesion to the skin and hardly being peeled, also good in releasability of the transdermal medicine into the body.  <P>SOLUTION: The first base material for pasting transdermal medicine in which a surface layer 2 consisting of an adhesive segmented polyurethane gel for containing the transdermal medicine, thinner than a first support layer 1, is laminated on and integrated with one surface of the support layer 1 consisting of the adhesive segmented polyurethane gel; has the surface layer made into a hydrophilic gel and the support layer made into an amphipathic or a lipophilic gel. The second base material for pasting transdermal medicine has a surface layer made into a lipophilic gel and a support layer made into an amphipathic or a hydrophilic gel. When the hydrophilic transdermal medicine is poured on the first base material and the lipophilic transdermal medicine is poured on the second base material, since the medicines essentially do not penetrate into the support layers but permeates the thin surface layers having affinity to the medicine and are contained in them, the amount of the medicines can be saved. Even though the surface layers are thin, they are backed up by the support layers and the adhesion to the skin is improved and hardly peeled off. Also, due to the thin surface layer, the transdermal medicine moves to releasing surface fast and is released.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The present invention relates generally to the method for the production of liposomal microencapsulated boron-containing products to be used for agricultural formulations. More specifically, a new method of production of liposomal microencapsulated is disclosed for active agents such as pesticides. A lecithin is mixed with an organic solvent in a certain proportion so as to provide solutions with varied levels of solubilized lecithin. The particular solvent being used will depend on the amount of active agent (AA) desired in the final solution. The formulation of the lecithin/organic solvent mixture is then allowed to settle. After settling, the top layer is separated and saved, while the bottom layer is discarded. An AA is then added to form a concentrate that is added to water for vesicle formation. Boron-containing materials formulated according to the invention may now be applied to agricultural field crops and fruit.
The invention provides an encoding gene of a BCR-ABL fusion protein mutant. A nucleotide sequence of the encoding gene is represented as the SEQ ID No.1. The invention also provides an expression carrier including the nucleotide sequence and a construction method thereof, and also provides the BCR-ABL fusion protein mutant. The BCR-ABL fusion protein mutant is designed on the basis of BCR-ABL/c-ABL SH3 structural domain locus mutation. Threonine at the 79th position of the ABL SH3 structure is mutated into tyrosine, wherein an amino acid sequence of the tyrosine is represented as the SEQ ID No.2. A constructed BCR-ABL fusion protein mutant is competitively combined with R1N1 for directly blocking and reducing combination of intracellular R1N1 and BCR-ABL. With combination of IM, sensitivity of cells on the IM is further increased, apoptosis of tumor cells are promoted and meanwhile potential complications caused by direct knockout of an R1N1 gene are overcome.
OBJECTIVE: Sacral neuromodulation (SNM) has emerged as an effective therapy for refractory lower urinary tract dysfunction (LUTD). Remote programming holds promise in addressing the time and economic burdens associated with outpatient programming, especially for patients in the observation period following Stage I implant surgery (where the lead is implanted first without the pulse generator). The study aimed to explore the effectiveness and patient satisfaction of remote programming for Stage I SNM patients, and analyze the benefits patients gain from remote programming.
METHODS: This prospective study was conducted at multiple high-level clinical SNM centres in China. Patients requiring SNM implantation were enroled and divided into two groups based on patient preference: remote programming (RP) group and outpatient control (OC) group. Patient attitudes toward RP were assessed through questionnaires, and the degree of symptom improvement was compared between the two groups to explore the usability of RP.
RESULTS: A total of 63 participants from 6 centres were included in the study, with 32 belonging to the RP group. The remote programming system presents a high level of usability (98%) and willingness (satisfaction rate: 96.83%) in result of questionnaire. RP showed a significant advantage in improving patients' score of ICSI/ICPI (medianΔICSI/ICPI RP vs. OC= -13.50 vs -2, P =0.015). And slightly ameliorate urinary symptoms such as pain (medianΔVAS RP vs. OC= -1 vs 0, P = 0.164) and urgency (medianΔOBASS -2.5 vs. -1, P = 0.,229), but the difference was not statistically significant. RP did not significantly impact the quality of life of patients ( P =0.113), so do the rate of phase-two conversion ( P = 0.926) or programming parameters.
CONCLUSION: To the best of our knowledge, the presented study is the first multicenter research focusing on the remote programming of Stage I SNM patients. Through the clinical implementation and patient feedback, we demonstrate that remote programming is not inferior to in-person programming in terms of success rate, effectiveness, safety, and patient satisfaction.
Soluble Intercellular Adhesion Molecule-1 (sICAM-1) has emerged as an inflammatory biomarker of many essential functions. We investigated the level of sICAM-1 influenced by Clonorchis sinensis (C. sinensis) co-infection in chronic hepatitis B (CHB) patients to explore the degree of liver tissue inflammation and liver function damage after co-infection. The study included data from patients with C. sinensis mono-infection (n=27), hepatitis B virus (HBV) mono-infection (n=32), C. sinensis and HBV co-infection (n=24), post-hepatitis B liver cirrhosis (n=18), post-hepatitis B liver cirrhosis co-infected with C. sinensis (n=16), and healthy controls (n=39). The level of sICAM-1 was measured with specific enzyme-linked immunosorbent assay method. Compared to the healthy control group, all the experimental groups had significantly higher serum sICAM-1 levels. The levels of sICAM-1 in co-infected groups were significantly higher compared to the mono-infection groups and were positively correlated with the levels of glutamate aminotransferase (ALT) and aspartate aminotransferase (AST). Our research findings confirmed that co-infection could exacerbate liver tissue inflammation and liver function damage in patients, could raise the sICAM-1 level, and may lead to the chronicity of HBV infection. These results provide clues for pathological mechanism study and formulating treatment plans.
Patients receive erlotinib hydrochloride PO QD on days 1-21 and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
A marker delivery device includes an elongated delivery cannula which has a distal end section, an inner lumen and a discharge opening in the distal end section in communication with the inner lumen. A plunger is slidably disposed within the inner lumen of the elongated delivery cannula. The plunger has a distal end. At least one elongated fibrous marker body is pre-formed prior to being inserted into the inner lumen of the elongated delivery cannula. The at least one elongated fibrous marker body is slidably disposed within the inner lumen of the elongated delivery cannula at a location distal to the distal end of the plunger. The pre-formed at least one elongated fibrous marker body includes a fibrous material compressed and impregnated with a binding agent and freeze dried in the compressed condition. A releasable plug is disposed within a distal portion of the inner lumen and distal to the at least one elongated fibrous marker body.
BACKGROUND: To better understand the preventive or therapeutic clinical interventions that may be supported by the association between rheumatoid arthritis (RA) and postural deformities including hallux valgus, flat foot, and scoliosis, this study was conducted using Mendelian randomization (MR) analysis. It aimed to investigate whether RA is causally associated with postural deformities in European populations.
METHODS: Summary-level data on RA and postural deformities were obtained from the IEU OpenGWAS project and Finngen database, respectively. LDSC regression analysis was conducted to assess the genetic correlation between these diseases. The inverse variance weighting (IVW) method was employed as the primary approach for two-sample MR analyses to evaluate causality. Supplementary methods included MR-Egger, maximum likelihood, weighted median, and cML-MA. To test for potential horizontal pleiotropy, we performed the MR-Egger intercept test, cML-MA, and secondary analyses after excluding confounders. Additionally, mediation analyses were conducted using two-step MR.
RESULTS: The IVW method revealed RA to be causally associated with hallux valgus (OR 1.132, 95% CI 1.087-1.178, P < 0.001) and flat foot (OR 1.197, 95% CI 1.110-1.291, P < 0.001). Among postural deformities, hallux valgus was causally associated with flat foot (OR 1.823, 95% CI 1.569-2.119, P < 0.001) and scoliosis (OR 1.150, 95% CI 1.027-1.287, P < 0.05). No significant horizontal pleiotropy was detected. Moreover, mediation analyses indicated that hallux valgus mediates the effect of RA on flat foot (mediation effect 0.024, 95% CI 0.005-0.044, P < 0.05), with a mediation proportion of 41.31%.
CONCLUSION: These findings indicate a potential causal association between genetically predicted RA and both hallux valgus and flat foot. Furthermore, hallux valgus serves as a mediator in the pathway from RA to flat foot. This underscores the importance of early screening and preventive treatment of foot deformities in RA patients. Further research is necessary to determine the applicability of these findings in non-European populations.
Natural spring medicinal waters are reinforced by addn. of curative plant extracts, vitamins and other nutrients to provide the constituents required for restorative or tonic purposes and supporting the active substances of the natural water. The mixt. may be conc. even to dryness and the dry residue formulated as powders, tablets or dragees. The natural water may be replaced by a synthetic soln. of similar compsn.
Participants received 1 or 2 doses of CUSA-081, 0.70 milligrams (mg) per 2 milliliter (mL) directly into the catheter lumen. Participants received the first dose at minute (min) 0, and the second dose, if needed, at min 90. Assessments were performed at min 30, 60, 90, 120, 150, and 180.
This study will aid in the evaluation of determining the accuracy of these miRNAs in pediatric patients and help in establishing pilot data for additional studies in the future. The testing will include blood samples, urine samples and buccal swabs from patients who meet eligibility at 5 time points to analyze biomarkers. Study participants will receive standard of care with antimicrobials and any additional appropriate cardiovascular or respiratory support per the clinical team. The samples will collected and stored at -80 until analysis can be performed. In addition to, during the course of the hospitalization, the enrolled patient will have data collected to calculate severity scores, including updated Pediatric Risk of Mortality (PRISM III) scores and simplified Therapeutic Intervention Scoring System(TISS-28) scores. All patient information will be de-identified. A standard procedure manual will be developed detailing the methods for data collection and entry. Data will be recorded in a de-identified manner on a Microsoft Excel database on a secure institutional server by the institutional staff. Data will then be analyzed to determine correlation of biomarkers to morbidity and mortality for these patients.
In one example, medical records or other types of data may be shown on a configurable timeline. The particular way in which data is organized on the timeline (e.g., by year, by quarter, by month, etc.) may be configured by a user. The timeline may support two levels of chronological organization (referred to as “groups” and “slots”), where the data is placed on the timeline according to both its group and its slot. For example, if a group is a calendar year and a slot is a calendar quarter, the data may be placed on the timeline in a way that visually shows both the year and the quarter to which the data relates. The data may be filtered according to a configurable filter, so that data records are shown, or not shown, on the timeline depending on whether the records satisfy the filtering criteria.
THIS IS ONLY ARM RECRUITING In Arm D, patients will be treated with 4 cycles of therapy. Methotrexate (3.5 g/m2) will be given at Dday 1 and Dday 15 of each cycle. Rituximab (500 mg/m2) will be given at Dday 0 and Dday 15 of each cycle. Vincristine (1.4mg/m2) will be given at Dday 1 and 15 of cycle 1 and 2 only. Procarbazine (100mg/m2) will be given of Day 1 of each cycle. Ibrutinib will be dosed at 560 mg daily. Arm D will have a safety lead-in of 6 patients. If more than 1 of 6 subjects develop a dose limiting toxicity (DLT) within the first 28 days of therapy (cycle 1), ibrutinib will be reduced to 420 mg daily dosing, and 6 additional patients will be enrolled. If more than 1 of 6 subjects develop a DLT, additional enrollment will be stopped.
Litopenaeus vannamei is a widely distributed euryhaline aquatic animal, affected by low salinity, which can impact its disease resistance and immunity. However, there is a limited understanding of the adaptation mechanisms of L. vannamei with different genetic backgrounds to low salinity. Therefore, the present study aimed to compare the immunity characteristics and transcriptomics of L. vannamei low salt-tolerant (FG I/J) and low salt-sensitive (control) families. Also, the disease resistance and immune parameters (including [THC], hemolymph cell viability, lysozyme activity [LZM], phenoloxidase content [PO], interleukin-6 [IL-6], and tumor necrosis factor-alpha [TNF-α]) of the FG I/J and control families of L. vannamei under low salinity (5‰) and ambient salinity (24‰) were examined. Additionally, hepatopancreas transcriptomics of the FG I/J and control families were analyzed at a salinity of 5‰. The results showed that the FG I/J family had higher disease resistance to Vibrio parahaemolyticus and stronger immunological capacity than the control family. Transcriptomic analysis showed significantly enriched energy metabolism and immune regulation pathways. Therefore, we speculated that energy metabolism provides sufficient energy for immunological modulation in the FG I/J family to deal with long-term low-salt stress and achieve high growth and survival rates.